Evidence map›Paper›PMID 29781207›Full record

ArticleAddiction (Abingdon, England)2018

Modelling the impact of a national scale-up of interventions on hepatitis C virus transmission among people who inject drugs in Scotland.

Hannah Fraser, Christinah Mukandavire, Natasha K Martin, David Goldberg, Norah Palmateer, Alison Munro, Avril Taylor, Matthew Hickman, Sharon Hutchinson, Peter Vickerman

Open access · greenAbstract read
In one paragraph

Article in Addiction (Abingdon, England), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
1.8field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 17 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Impact of Antiviral Therapy Scale-Up Among People Who Inject Drugs in Scotland: Regional Evidence of Hepatitis C Virus Elimination.Liver international : official journal of the International Association for the Study of the Liver · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 2 countries.

Hannah FraserPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-4340-9995
Christinah MukandavirePopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
Natasha K MartinPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.
David GoldbergHealth Protection Scotland, Glasgow, UK.
Norah PalmateerHealth Protection Scotland, Glasgow, UK.ORCID 0000-0003-4493-0173
Alison MunroSchool of Social Sciences, University of the West of Scotland, Paisley, UK.
Avril TaylorSchool of Media, Society and Culture, University of the West of Scotland, Paisley, UK.
Matthew HickmanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0001-9864-459X
Sharon HutchinsonSchool of Health and Life Sciences, Glasgow Caledonian University, Glasgow, UK.
Peter VickermanPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK.ORCID 0000-0002-8291-5890
University of Bristol · GBHealth Protection Scotland · GBUniversity of the West of Scotland · GBGlasgow Caledonian University · GBUniversity of San Diego · US

Funding

VirologyP30AI036214 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Maile Ann Young Karris · 1994 to 2026
$78.4M
Modeling Structural HIV Determinants in Substance Users and related populationsR01DA037773 · NIDA · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI MARTIN, NATASHA, STRATHDEE, STEFFANIE A. · 2015 to 2017
$1.4M
Department of Health RP-DG-0610-10055Department of Health RP-PG-0616-20008National Institute for Nealth Research Health Protection Research Unit in Evaluation of InterventionsNIAID NIH HHS P30 AI036214NIDA NIH HHS R01 DA037773Scottish Government Hepatitis C Action Plan
6 · The paper itself

Abstract

BACKGROUND AND

aimsTo reduce hepatitis C virus (HCV) transmission among people who inject drugs (PWID), Scottish Government-funded national strategies, launched in 2008, promoted scaling-up opioid substitution therapy (OST) and needle and syringe provision (NSP), with some increases in HCV treatment. We test whether observed decreases in HCV incidence post-2008 can be attributed to this intervention scale-up.

designA dynamic HCV transmission model among PWID incorporating intervention scale-up and observed decreases in behavioural risk, calibrated to Scottish HCV prevalence and incidence data for 2008/09.

settingScotland, UK.

participantsPWID. MEASUREMENTS: Model projections from 2008 to 2015 were compared with data to test whether they were consistent with observed decreases in HCV incidence among PWID while incorporating the observed intervention scale-up, and to determine the impact of scaling-up interventions on incidence.

findingsWithout fitting to epidemiological data post-2008/09, the model incorporating observed intervention scale-up agreed with observed decreases in HCV incidence among PWID between 2008 and 2015, suggesting that HCV incidence decreased by 61.3% [95% credibility interval (CrI) = 45.1-75.3%] from 14.2/100 person-years (py) (9.0-20.7) to 5.5/100 py (2.9-9.2). On average, each model fit lay within 84% (10.1/12) of the confidence bounds for the 12 incidence data points against which the model was compared. We estimate that scale-up of interventions (OST + NSP + HCV treatment) and decreases in high-risk behaviour from 2008 to 2015 resulted in a 33.9% (23.8-44.6%) decrease in incidence, with the remainder [27.4% (17.6-37.0%)] explained by historical changes in OST + NSP coverage and risk pre-2008. Projections suggest that scaling-up of all interventions post-2008 averted 1492 (657-2646) infections over 7 years, with 1016 (308-1996), 404 (150-836) and 72 (27-137) due to scale-up of OST + NSP, decreases in high-risk behaviour and HCV treatment, respectively.

conclusionsMost of the decline in hepatitis C virus (HCV) incidence in Scotland between 2008 and 2015 appears to be attributable to intervention scale-up (opioid substitution therapy and needle and syringe provision) due to government strategies on HCV and drugs.

Indexed as

Antiviral AgentsHarm ReductionHepacivirusHepatitis CHumansIncidenceModels, TheoreticalNeedle-Exchange ProgramsOpiate Substitution TreatmentOpioid-Related DisordersPrevalenceScotlandSubstance Abuse, IntravenousAntiviral AgentsHepatitis Cinjecting drug usersneedle and syringe programmesopioid substitution therapypeople who inject drugsScotland

Identifiers

PMID29781207
PMCPMC6250951
OpenAlexW2803733738

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.